Bortezomib Impurity 60, with the CAS number 2210228-73-0, is a chemical compound associated with the pharmaceutical agent bortezomib, which is primarily used in the treatment of multiple myeloma and certain types of lymphoma. As an impurity, it may arise during the synthesis or degradation of bortezomib and is typically characterized by its molecular structure, which may differ slightly from the parent compound. Impurities like this can affect the efficacy and safety of the drug, making their identification and quantification important in pharmaceutical development and quality control. The characteristics of Bortezomib Impurity 60 would include its molecular weight, solubility, and stability under various conditions, although specific values are not provided here. Analytical techniques such as HPLC, NMR, and mass spectrometry are commonly employed to characterize such impurities. Understanding these characteristics is crucial for ensuring the purity and safety of bortezomib formulations used in clinical settings.

Bortezomib Impurity 60

2210228-73-0: Bortezomib Impurity 60, with the CAS number 2210228-73-0, is a chemical compound associated with the pharmaceutical agent bortezomib, which is primarily used in the treatment of multiple myeloma and certain types of lymphoma. As an impurity, it may arise during the synthesis or degradation of bortezomib and is typically characterized by its molecular structure, which may differ slightly from the parent compound. Impurities like this can affect the efficacy and safety of the drug, making their identification and quantification important in pharmaceutical development and quality control. The characteristics of Bortezomib Impurity 60 would include its molecular weight, solubility, and stability under various conditions, although specific values are not provided here. Analytical techniques such as HPLC, NMR, and mass spectrometry are commonly employed to characterize such impurities. Understanding these characteristics is crucial for ensuring the purity and safety of bortezomib formulations used in clinical settings.

CAS 2210228-73-0

Bortezomib Impurity 60

Bortezomib Impurity 60

Ref: 4Z-B-4673

Bortezomib Impurity 60

Ref: ST-EA-CP-B34066